<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539993</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00014768</org_study_id>
    <nct_id>NCT01539993</nct_id>
  </id_info>
  <brief_title>Prospective Liver Study</brief_title>
  <official_title>Prospective Analysis of Liver Cancer Treatment and Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed for patients diagnosed with Liver cancer to collect information about
      the relationship between types of liver cancer, methods of treatment and outcomes over time.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess efficacy of percutaneous and transarterial treatments for liver cancer.</measure>
    <time_frame>1 month</time_frame>
    <description>QOL questionnaire will be collected during follow up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>long term follow up</measure>
    <time_frame>3 months, 6 months 1year</time_frame>
    <description>Patients will be administered QOL during 3 months, 6 months and 1 year follow up.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18 yrs and older with a diagnosis of Hepatocellular carcinoma and elegible for
        percutaneous liver treatments
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver
             treatment.

        Exclusion Criteria:

          -  Severe liver disfunction

          -  Active uncontrolled infection

          -  Significant underlying medical of physical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin S Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Hyun Kevin Kim</investigator_full_name>
    <investigator_title>MD FSIR, Director of Interventional Radiology and Image-Guided Medicine.</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Percutaneous treatments</keyword>
  <keyword>RFA</keyword>
  <keyword>TACE</keyword>
  <keyword>DEB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

